Skip to main content
GlaxoSmithKline PLC logo

GlaxoSmithKline PLC — Investor Relations & Filings

Ticker · GSK ISIN · GB00BN7SWP63 LEI · 5493000HZTVUYLO1D793 IL Manufacturing
Open in API
Filings indexed 7,016 across all filing types
Latest filing 2026-02-04 Earnings Release
Country GB United Kingdom
Listing IL GSK

About GlaxoSmithKline PLC

https://www.gsk.com/en-gb/

GSK plc is a global biopharmaceutical company that unites science, technology, and talent to research, develop, and manufacture medicines and vaccines. The company focuses on preventing and treating disease across four primary therapeutic areas: infectious diseases, HIV, oncology, and immunology/respiratory. Its portfolio consists of specialty medicines and vaccines aimed at addressing significant global health needs. GSK's strategy centers on leveraging its research and development capabilities to deliver new health solutions.

Recent filings

Filing Released Lang Actions
Final Results
Earnings Release Classification · 100% confidence The document is an official 'Results Announcement' from GSK PLC, detailing financial performance for the full year 2025 and Q4 2025. It includes key highlights such as sales, operating profit, EPS, R&D pipeline updates, dividend declarations, and future guidance. It is a comprehensive summary of financial results rather than a brief publication notice, and it is not a full 10-K annual report. Therefore, it is classified as an Earnings Release. FY 2025
2026-02-04 English
6-K Filing
Regulatory Filings
2026-02-04 English
Total Voting Rights
Regulatory Filings Classification · 98% confidence The document is a 'Total Voting Rights' announcement issued by GSK plc in compliance with the Financial Conduct Authority's Disclosure Guidance and Transparency Rule 5.6.1R. It provides the total number of voting rights and issued share capital to assist shareholders with regulatory notification requirements. While it relates to share capital, it is a standard regulatory disclosure of voting rights rather than a specific share issuance or repurchase event, and it does not fit into the other specific categories like DVA (which is for results of votes cast) or SHA (which is for new issues). Therefore, it is classified as a Regulatory Filing (RNS).
2026-02-02 English
SC TO-T Filing
Regulatory Filings
2026-02-02 English
6-K Filing
Regulatory Filings
2026-02-02 English
European Commission approves Arexvy for adults 18+
Regulatory Filings Classification · 100% confidence The document is a press release issued via the London Stock Exchange's Regulatory News Service (RNS). It announces a specific regulatory milestone: the European Commission's approval for the expanded use of GSK's RSV vaccine, Arexvy. As this is a general corporate announcement regarding product regulatory approval and does not fit into specific categories like financial reports, dividends, or M&A, it falls under the 'Regulatory Filings' (RNS) category.
2026-01-26 English

Browse filings by year

27 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.